Dr. Krishnansu Sujata Tewari, MD

Dr. Tewari practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Tewari's NPI, 1205868445, was assigned on July 7, 2006. Dr. Tewari graduated from UC Irvine School of Medicine in 1994. Dr. Tewari's California license number on file is A601614.

Dr. Tewari's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Tewari's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Tewari is also affiliated with Providence St. Joseph Hospital Orange. The medical group on file is OB/GYN University Associates.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tewari practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Tewari's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Tewari is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Tewari has a license on file in California.

Dmand AI lists hysterectomy, menopause, ovarian cyst and UTI among the conditions Dr. Tewari treats.

CMS data shows 370 Medicare services from Dr. Tewari across 4 procedure codes in 2024, for 162 Medicare patients. Medicare paid $24,434 for them.

CMS counts 162 Medicare patients who saw Dr. Tewari in 2024. The largest group is 65 to 74, with 96 patients. 73% of them have high cholesterol, and 70% have high blood pressure. 32% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tewari's median patient age at 61, with 100% women.

In 2024, Dr. Tewari wrote 64 Medicare Part D claims for 25 patients. 83% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $50 in total drug cost. In 2022, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tewari for performance year 2024, reported through an alternative payment model (APM). Dr. Tewari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tewari as offering telehealth. CMS counts 17 procedures of removal of the uterus by Dr. Tewari, more than 90% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 234 papers to Dr. Tewari, published from 2008 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Uterine Cervical Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Ovarian Neoplasms. Dr. Tewari has published most often in Gynecol Oncol. Dr. Tewari's most frequent co-authors are Bradley J. Monk, MD, Robert A. Burger, MD and Ramez Nassef Eskander, MD.

Dmand AI links Dr. Tewari to 9 clinical trials, 4 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Uterine Cervical Neoplasms, Uterine Cervical Diseases and Adenocarcinoma, Clear Cell. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Tewari that name 1 trial.

CMS Open Payments shows 542 general payments to Dr. Tewari from 23 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Merck Sharp & Dohme Corporation paid the most, $147,701. It also lists 41 research payments totaling $21,458 from 2017 to 2025, naming 1 clinical trial.

Dmand AI lists 23 awards for Dr. Tewari, most recently Best Doctors in America in 2018.

Dr. Tewari graduated from UC Irvine School of Medicine in 1994. Dr. Tewari is a member of ACS and ASCO.

Dr. Tewari is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.